CoChat

Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease

Richardson, D.R., Ponka, P. · 1998 · Journal of Laboratory and Clinical Medicine

The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.

Abstract

At present, the only iron (Fe) chelator in clinical use for the treatment of Fe overload disease is the tris-hydroxamate deferoxamine (DFO). However, DFO suffers from a number of disadvantages, including the need for subcutaneous infusion (12 to 24 hours a day, 5 or 6 times per week), its poor intestinal absorption, and high cost. Therefore, there is an urgent need for an efficient, economical, and orally effective Fe chelator. Pyridoxal isonicotinoyl hydrazone (PIH) is a tridentate Fe-chelating agent that shows high Fe chelation efficacy both in vitro in cell culture models and also in vivo in rats and mice. In addition, this chelator is relatively nontoxic, economical to synthesize, and orally effective, and it shows high selectivity and affinity for Fe. However, over the last 10 years the development of PIH and its analogs has largely been ignored because of justifiable interest in other ligands such as 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Unfortunately, recent clinical trials have shown that significant complications occur with L1 therapy, and it is controversial whether this chelator is effective at reducing hepatic Fe levels in patients. Because of the current lack of a clinically useful Fe chelator to replace DFO, PIH and its analogs appear to be potential candidate compounds that warrant further investigation. In this review we will discuss the studies that have been performed to characterize these chelators at the chemical and biologic levels as effective agents for treating Fe overload. The evidence from the literature suggests that these ligands deserve further careful investigation as potential orally effective Fe chelators.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0022-2143(98)90180-9

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 68 references

Research works printed but not linked: 6

  1. Olivieri, 1996, Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major [abstract], Blood, 88, 651a
  2. Olivieri, 1996, Long-term follow-up of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1) [abstract], Blood, 88, 1229a
  3. World Health Organization, 1983, Community control of hereditary anaemias, Bull WHO, 61, 63
  4. Webb, 1988, Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator, Birth Defects, 23, 63
  5. Sharma, 1989, Enteral pyridoxal isonicotinoyl hydrazone (PIH) is an effective chelator in experimental iron overload by promotion of biliary iron excretion [abstract], Hepatology, 10, 573
  6. Hider, 1982, UK Patent: GB-2118176

Cited by

See all 126

Metadata

Authors
Richardson, D. R., & Ponka, P.
Affiliations
Royal Brisbane and Women's Hospital (AU)
Corresponding author
Richardson, D.R.
Venue
Journal of Laboratory and Clinical Medicine
Publisher
Elsevier BV
Published
1998-04
Volume
131
Issue
4
Pages
306-315
ISSN
0022-2143 (ISSN-L)
OpenAlex
W1995087031
Cited by
126
References
69
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 3 · 2015: 2 · 2014: 5 · 2013: 2 · 2012: 2
FWCI
2.36
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Laboratory and Clinical Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
Keywords
pyridoxal isonicotinoyl hydrazone, iron chelators, oral iron chelation
MeSH terms
Animals, Iron Chelating Agents, Isoniazid, Pyridoxal, Iron Overload, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. https://app.cochat.ai/papers/10.1016/s0022-2143(98)90180-9
The paper
Richardson, D. R., & Ponka, P. (1998). Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. Journal of Laboratory and Clinical Medicine. https://doi.org/10.1016/s0022-2143(98)90180-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.